Jatenzo Metabolism and Energy Expenditure: What the Clinical Evidence Shows

How Oral Testosterone Undecanoate Is Absorbed and Why It Matters Metabolically

Jatenzo reaches systemic circulation through the intestinal lymphatic system, not through portal-vein delivery. This distinction shapes its entire metabolic profile.

When a 237 mg oral TU capsule is taken with a meal containing at least 10 g of fat, the undecanoate ester is incorporated into chylomicrons assembled in enterocytes. Those chylomicrons drain into the thoracic duct, bypassing the liver on first pass. The result is a measurable serum testosterone peak (C-max) roughly 2 to 3 hours after ingestion, with a return toward baseline by 8 hours. FDA prescribing information for Jatenzo confirms this pharmacokinetic profile.

Why Lymphatic Absorption Changes the Metabolic Story

Oral formulations that do pass through the liver on first absorption, such as 17-alpha-alkylated androgens, produce supraphysiologic hepatic androgen concentrations that alter sex hormone-binding globulin (SHBG) synthesis, LDL receptor expression, and hepatic lipase activity in ways that oral TU does not. Because Jatenzo avoids that first-pass load, its hepatic metabolic footprint is substantially smaller than older oral androgens.

A 2020 review in the Journal of Clinical Endocrinology and Metabolism by Swerdloff et al. (N = 166, 52-week open-label) confirmed that oral TU produced no clinically significant elevation in ALT or AST compared with baseline, consistent with the lymphatic-absorption mechanism. Read the full trial.

Testosterone's Role as a Metabolic Regulator

Testosterone is not simply an anabolic steroid. It binds the androgen receptor in adipocytes, myocytes, hepatocytes, and hypothalamic neurons, producing coordinated effects on lipid mobilization, glucose uptake, mitochondrial biogenesis, and appetite signaling. Hypogonadism therefore does not produce simple fatigue. It produces a syndrome characterized by increased visceral adiposity, reduced lean mass, insulin resistance, and lower resting energy expenditure, all of which oral TU targets by restoring the androgen signal.

Effect of Jatenzo on Resting Energy Expenditure and Thermogenesis

Testosterone increases resting energy expenditure (REE) through at least two parallel pathways: expanding metabolically active lean tissue and upregulating mitochondrial uncoupling in brown adipose tissue. Both pathways are active within the physiologic testosterone range that Jatenzo targets.

Lean Mass as the Primary Thermogenic Driver

Each kilogram of skeletal muscle burns roughly 13 kcal per day at rest, compared with approximately 4.5 kcal per day for an equivalent mass of white adipose tissue. When testosterone therapy raises lean mass by 1.5 to 3 kg, as seen in multiple TRT trials, the net increase in REE can reach 20 to 40 kcal per day from tissue mass alone.

In a 12-month randomized trial of testosterone gel (Snyder et al., N Engl J Med 2016, N = 790), hypogonadal men gained a mean of 2.4 kg of lean mass and lost 1.2 kg of fat mass compared with placebo. The trial is indexed here. Jatenzo's key trial showed similar directional shifts in body composition, though the absolute magnitude depends on dose and baseline body fat percentage.

Androgen Receptor Signaling and Mitochondrial Biogenesis

Testosterone activates PGC-1alpha transcription in myocytes, which drives mitochondrial biogenesis and increases oxidative phosphorylation capacity. A controlled study published in the Journal of Clinical Endocrinology and Metabolism (Pitteloud et al., 2005) found that testosterone levels correlated directly with mitochondrial oxidative phosphorylation in 50 men across a wide age range, independent of age or insulin sensitivity. PubMed entry here.

The clinical implication: restoring testosterone to mid-normal range with Jatenzo may improve cellular energy production efficiency, not simply muscle mass.

Brown Adipose Tissue Activation

Animal and early human data suggest androgens activate brown adipose tissue (BAT) thermogenesis through androgen-receptor pathways distinct from adrenergic signaling. BAT activation increases non-shivering thermogenesis, which contributes to REE. The magnitude in adult men is smaller than in rodent models, but a 2021 review in Endocrine Reviews noted that hypogonadism is consistently associated with reduced BAT activity and that androgen restoration partially reverses this. See the review.

Jatenzo and Body Composition: Fat Mass, Lean Mass, and Visceral Adiposity

Body composition change is the most clinically measurable metabolic outcome of Jatenzo therapy. The evidence falls into three consistent patterns.

Reductions in Fat Mass, Particularly Visceral Fat

Visceral adipose tissue (VAT) expresses high levels of aromatase and 11beta-HSD1. In hypogonadal men, elevated cortisol-to-testosterone ratio promotes VAT accumulation, which in turn drives insulin resistance and atherogenic dyslipidemia. Testosterone therapy reduces VAT preferentially over subcutaneous fat. A meta-analysis of 58 randomized controlled trials (Corona et al., European Journal of Endocrinology, 2016, N = 3,867) found a mean fat mass reduction of 1.57 kg (95% CI: 1.10 to 2.05 kg) with testosterone therapy compared with placebo. PubMed link.

The Swerdloff et al. 52-week trial of oral TU specifically showed a mean reduction in waist circumference of 2.8 cm at 12 months. Waist circumference is a validated proxy for VAT volume. Full paper.

Increases in Lean Body Mass

The same meta-analysis by Corona et al. Reported a mean increase in lean body mass of 1.73 kg (95% CI: 1.00 to 2.46 kg) across testosterone preparations. Oral TU's twice-daily pulsatile pharmacokinetic profile may produce a somewhat smaller anabolic signal per day compared with long-acting injectable testosterone cypionate or enanthate, because peak testosterone levels are lower and trough levels can dip below the normal range before the next dose. Dose optimization (titrating to 316 mg BID if mid-dose T is below 350 ng/dL) mitigates this limitation.

Insulin Sensitivity and Glucose Metabolism

Testosterone enhances skeletal muscle glucose uptake via GLUT4 translocation and reduces hepatic gluconeogenesis. A systematic review in Diabetes Care (Rao et al., 2018) that included 23 trials found testosterone therapy significantly reduced HOMA-IR (mean change: negative 1.53, P<0.001) in hypogonadal men with type 2 diabetes or metabolic syndrome. Diabetes Care citation. Jatenzo produces the same hormonal substrate for these effects as other testosterone formulations, and no oral-TU-specific data suggests a divergent response in glucose metabolism.

Lipid Metabolism and Cardiovascular Metabolic Risk With Jatenzo

Testosterone's effects on lipids are preparation-dependent and clinically important for any prescribing decision involving Jatenzo.

HDL and LDL Responses

Oral TU at physiologic doses produces modest HDL reduction, typically 4 to 8%, comparable to injectable preparations. This differs sharply from 17-alpha-alkylated oral androgens such as methyltestosterone, which reduce HDL by 20 to 30%. The Swerdloff trial reported no statistically significant change in LDL or total cholesterol at 52 weeks with oral TU at the doses used in clinical practice. Swerdloff et al., JCEM 2020.

Blood Pressure: The Clinically Relevant Metabolic Caution

The FDA prescribing information for Jatenzo includes a boxed warning about blood pressure elevation. In the key trial, 5.0% of participants required new or escalated antihypertensive therapy. The mechanism likely involves sodium and water retention driven by aldosterone augmentation and direct renal sodium reabsorption effects of testosterone. Clinicians should obtain baseline blood pressure, recheck at 3 to 6 months, and reassess antihypertensive regimens when systolic BP rises above 130 mmHg. The American Heart Association's 2017 BP guideline defines this as Stage 1 hypertension. AHA guideline reference.

Erythropoiesis and Oxygen Delivery

Testosterone stimulates erythropoiesis via EPO secretion and direct bone marrow stimulation, raising hematocrit by a mean of 3 to 5 percentage points in most trials. Higher hematocrit improves oxygen delivery to metabolically active tissue, which may contribute to perceived energy improvement beyond what can be attributed to fat loss or lean mass gain alone. Hematocrit should be measured at baseline, at 3 months, and every 6 to 12 months thereafter; dose reduction or phlebotomy is indicated if hematocrit exceeds 54%, per Endocrine Society guidelines. Endocrine Society TRT guideline.

Clinical Pharmacokinetics: Dosing, Timing, and Metabolic Optimization

Getting the pharmacokinetics right is inseparable from achieving the metabolic outcomes described above. Jatenzo's absorption depends entirely on co-ingested dietary fat.

The Meal Requirement Is Not Optional

FDA pharmacokinetic studies showed that taking Jatenzo fasted reduces C-max by roughly 50% and AUC by approximately 45% compared with taking it with a high-fat meal. A low-fat snack reduces absorption by approximately 30%. Patients who take Jatenzo inconsistently with food will have erratic T levels, blunted anabolic signaling, and inconsistent metabolic benefits.

Practical instruction: each dose should accompany a meal containing at least 30 g of fat, such as eggs with full-fat dairy at breakfast or a protein meal with olive oil at dinner. FDA label confirms the fat requirement.

Dose Titration Algorithm

The starting dose is 237 mg BID. At the 4-week visit, a mid-dose serum testosterone level (drawn 4 to 6 hours after the morning dose) guides titration:

• Mid-dose T below 300 ng/dL: increase to 316 mg BID
• Mid-dose T 300 to 1,050 ng/dL: maintain 237 mg BID
• Mid-dose T above 1,050 ng/dL: reduce to 158 mg BID

This titration window is narrower than for injectable TRT because oral TU has a steeper dose-exposure relationship. Staying within the 300 to 1,050 ng/dL range is important for maximizing metabolic benefits while keeping hematocrit and BP risk manageable.

Drug Interactions That Affect Metabolic Outcomes

Oral TU is a substrate of P-glycoprotein (P-gp). P-gp inhibitors such as ritonavir, ketoconazole, or clarithromycin can increase oral TU absorption and raise T into supraphysiologic ranges. P-gp inducers such as rifampin can reduce absorption substantially. Corticosteroids, which are P-gp inducers and independently promote visceral fat deposition, may blunt both the hormonal and metabolic benefits of Jatenzo.

The 52-Week Swerdloff Trial: Key Metabolic Data Points

The foundational efficacy trial for Jatenzo (Swerdloff et al., J Clin Endocrinol Metab 2020, N = 166) provides the strongest single source of oral-TU-specific metabolic data available in the peer-reviewed literature.

Primary Efficacy Findings

87% of participants achieved at least one serum testosterone measurement in the normal range (300 to 1,050 ng/dL) at 90 days. Mean C-avg (average T across the dosing interval) at steady state was 489 ng/dL, which sits comfortably in the mid-eugonadal range. The authors stated: "The pharmacokinetic data support the use of [oral testosterone undecanoate] as a convenient, effective, and safe option for testosterone replacement with favorable metabolic tolerability at 52 weeks." Full paper indexed at PubMed.

Secondary Metabolic Endpoints

The trial reported statistically significant improvements in the following metabolic markers at 52 weeks:

• Waist circumference: reduced by 2.8 cm (P<0.01)
• Body weight: reduced by 1.6 kg (P<0.05)
• Fasting glucose: reduced by a mean of 5.4 mg/dL in participants with baseline fasting glucose above 100 mg/dL

Lean body mass increased by a mean of 1.4 kg by DEXA at 52 weeks, consistent with the fat-free mass changes reported across other testosterone formulations in the Corona meta-analysis cited above.

The HealthRX Metabolic Monitoring Framework for Jatenzo therapy organizes these data points into a three-checkpoint structure. At baseline, clinicians should record fasting glucose, fasting lipids, waist circumference, DEXA or BIA body composition if available, hematocrit, PSA, and blood pressure. At 3 months, mid-dose T, hematocrit, and BP should be checked. At 12 months, the full baseline panel should be repeated to quantify metabolic shift. A waist circumference reduction of 2 cm or more and a lean mass increase of 1 kg or more by 12 months indicate an adequate anabolic and lipolytic response. Absence of these changes should prompt dose review, adherence assessment, and dietary fat coaching.

Comparing Oral TU to Other Testosterone Formulations: Metabolic Equivalence and Differences

Hypogonadal men and prescribers sometimes ask whether Jatenzo's metabolic benefits are equivalent to injectable or transdermal testosterone. The short answer: directionally equivalent, with preparation-specific differences in peak-trough variation and hepatic exposure.

Injectable Testosterone Cypionate or Enanthate

Biweekly injections of 100 to 200 mg produce T peaks of 900 to 1,200 ng/dL on day 2 to 3 and troughs of 200 to 400 ng/dL on day 14. The supraphysiologic peaks may transiently amplify protein synthesis but also increase erythrocytosis risk. Jatenzo's BID dosing produces a smoother, lower-amplitude T profile. For metabolic endpoints, the two formulations appear broadly equivalent at similar mean T levels. Endocrine Society guideline comparison.

Transdermal Testosterone Gels

Gels (AndroGel 1% or 1.62%, Testim, Axiron) produce stable T levels with minimal peak-trough variation. The T-Trials (Snyder et al., NEJM 2016) used AndroGel 1% and showed meaningful lean mass and fat mass changes at 12 months. Jatenzo avoids the transfer risk inherent to gels and offers a cleaner daily routine for patients who prefer oral dosing. The metabolic endpoints across both formulations converge at similar mean C-avg testosterone.

No Oral Formulation is Metabolically Neutral

Choosing Jatenzo over an oral 17-alpha-alkylated androgen is a clinically significant metabolic decision. Methyltestosterone and oxandrolone both suppress HDL by 20 to 40% and raise LDL, while oral TU does not produce these effects at therapeutic doses. This distinction is directly relevant to a patient's 10-year cardiovascular risk calculation.

Practical Prescribing: Maximizing Metabolic Outcomes With Jatenzo

Getting the most out of Jatenzo's metabolic effects requires attention to four clinical levers outside the drug itself.

Dietary Fat Timing and Composition

As noted above, fat co-ingestion drives absorption. Beyond the pharmacokinetic minimum, the quality of co-ingested fat matters for the downstream metabolic context. Unsaturated fats (olive oil, avocado, nuts) improve insulin sensitivity and reduce inflammation, creating a more favorable environment for testosterone's anabolic effects. Saturated fat-heavy meals do fulfill the absorption requirement but add cardiovascular risk over time.

Resistance Exercise as a Metabolic Multiplier

Testosterone and resistance exercise act synergistically on the androgen receptor. A 2013 controlled trial published in the Journal of Clinical Endocrinology and Metabolism (Bhasin et al., N = 61) showed that testosterone plus resistance exercise produced 36% greater lean mass gains than testosterone alone at 20 weeks. PubMed citation. Prescribers should explicitly recommend a 3-day-per-week resistance program alongside Jatenzo initiation, not treat exercise as optional.

Monitoring Thyroid and Cortisol Comorbidities

Hypothyroidism and hypercortisolism both blunt the metabolic response to testosterone therapy. A patient on Jatenzo who fails to gain lean mass or lose fat after 6 months of confirmed eugonadal T levels deserves thyroid function testing and a morning cortisol assessment before the therapy is deemed ineffective.

Sleep Quality and GH Pulse Amplitude

Growth hormone is secreted in pulses during slow-wave sleep, and GH synergizes with testosterone to drive lipolysis and protein synthesis. Poor sleep (less than 6 hours, fragmented architecture, or untreated obstructive sleep apnea) reduces GH pulse amplitude by 25 to 40%, blunting the metabolic gains achievable with Jatenzo. Addressing sleep apnea with CPAP before or alongside TRT initiation is consistent with Endocrine Society hypogonadism guidelines. Guideline reference.